Gilead Sciences, Inc.

TSX:GILD Stock Report

Market Cap: CA$253.8b

Gilead Sciences Past Earnings Performance

Past criteria checks 0/6

Gilead Sciences's earnings have been declining at an average annual rate of -4.8%, while the Biotechs industry saw earnings growing at 34.4% annually. Revenues have been growing at an average rate of 2.1% per year.

Key information

-4.84%

Earnings growth rate

-4.60%

EPS growth rate

Biotechs Industry Growth51.09%
Revenue growth rate2.10%
Return on equity-27.59%
Net Margin-10.64%
Last Earnings Update30 Jun 2026

Recent past performance updates

Recent updates

Seeking Alpha • Jul 30

Gilead: Buy The Distortion Before Q2 Clears It Up

Summary Gilead Sciences is a buy, as a temporary $11.5 billion IPR&D charge distorts optics but not fundamentals. GILD's HIV franchise is growing 8% with patent protection through 2036 and up to seven new launches by 2033. Oncology inflection is underway, led by Trodelvy's first-line expansion and strategic acquisitions building a next-gen pipeline. At 14.5x normalized forward earnings, GILD trades at a 20–25% discount to peers despite superior margins and growth visibility. Read the full article on Seeking Alpha

Revenue & Expenses Breakdown

How Gilead Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSX:GILD Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2630,457-3,2406,4605,944
31 Mar 2629,7369,2165,9125,704
31 Dec 2529,4438,5105,7085,688
30 Sep 2529,0878,1105,7925,734
30 Jun 2528,8636,3115,8505,786
31 Mar 2528,7355,9655,8605,685
31 Dec 2428,7544806,0005,816
30 Sep 2428,2991265,7195,655
30 Jun 2427,8051,0545,6245,728
31 Mar 2427,4504856,1055,778
31 Dec 2327,1165,6656,0625,758
30 Sep 2327,3915,8766,5025,895
30 Jun 2327,3825,4846,4015,578
31 Mar 2327,0435,5835,9095,280
31 Dec 2227,2814,5925,6734,977
30 Sep 2227,1363,3345,3034,768
30 Jun 2227,5154,1375,2804,727
31 Mar 2227,4724,5155,2744,714
31 Dec 2127,3056,2255,2464,601
30 Sep 2127,4827,3945,0834,655
30 Jun 2126,6385,1624,9994,713
31 Mar 2125,5643014,8874,924
31 Dec 2024,6891235,1124,927
30 Sep 2023,1471,2684,6254,560
30 Jun 2022,174-2574,5714,432
31 Mar 2022,7164,9624,4274,002
31 Dec 1922,4495,3864,3814,055
30 Sep 1922,3652,6934,3084,086
30 Jun 1922,3575,9554,2043,995
31 Mar 1922,3205,8924,0894,318
31 Dec 1822,1275,4554,0563,920
30 Sep 1822,2811,5874,1774,218
30 Jun 1823,1972,2084,1084,068
31 Mar 1824,6903,4644,0253,740
31 Dec 1726,1074,6283,8783,734
30 Sep 1727,47811,6013,6183,591
30 Jun 1728,46612,2133,5703,826
31 Mar 1729,10112,6373,5634,446
31 Dec 1630,39013,5013,3984,666
30 Sep 1631,57615,0763,4724,416
30 Jun 1632,37116,3463,5444,135
31 Mar 1632,83917,3413,4663,469
31 Dec 1532,63918,1083,4263,014
30 Sep 1531,44716,9123,2362,952

Quality Earnings: GILD is currently unprofitable.

Growing Profit Margin: GILD is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: GILD is unprofitable, and losses have increased over the past 5 years at a rate of 4.8% per year.

Accelerating Growth: Unable to compare GILD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GILD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (67.9%).

Return on Equity

High ROE: GILD has a negative Return on Equity (-27.59%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/16 12:28
End of Day Share Price 2026/09/16 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gilead Sciences, Inc. is covered by 64 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Brian SkorneyBaird
James BirchenoughBarclays